Fukuoka Noriyasu, Uno Junji, Tsukamoto Toyohisa, Houchi Hitoshi, Kimura Michio, Morita Shushi
Department of Pharmacy, Kagawa University Hospital, Kagawa, Japan.
Ther Drug Monit. 2009 Feb;31(1):57-62. doi: 10.1097/FTD.0b013e3181947772.
This study sought a suitable physiological parameter related to daily phenytoin (PHT) dose (D) providing a steady-state serum concentration (Ct) and analyzed the influences of coadministered antiepileptic drugs on Ct quantitatively to adjust PHT dose. Data were derived from a total of 368 patients with epilepsy treated with multiple oral administrations of PHT. Phenobarbital, carbamazepine, valproic acid, zonisamide, clonazepam, and ethosuximide were coadministered. For the administration of PHT alone, 4 types of parameter, that is, total body weight, total body water volume, body surface area, and extracellular water volume (VECW) were examined. Then, a Michaelis-Menten kinetic model was postulated including VECW, which was assumed to detect the effect of the coadministered drug quantitatively. Adopting VECW as a transforming factor, the concentration to dose (L:D) ratio [Ct/(D/VECW)] was independent of the patient's age and gender in relation to Ct and expressed as Ct/(D/VECW) = 0.0245 x Ct + 0.076. Analysis clarified that ratios were estimated as 0.90, 0.91, 0.89, and 0.84 for phenobarbital, carbamazepine, valproic acid, and zonisamide, respectively, to maintain the same Ct concentration of PHT. Influences were not detected as the number (> or =2) of coadministered drugs increased, regardless of factor type. PHT clearance changed in an age-dependent manner and was usually poorly correlated with weight-based doses. VECW was more closely correlated with age-dependent changes in physiological parameters such as clearance. VECW was considered to remove the influence of age on clearance, and estimated ratios could be used for all age groups. In the case of the addition or removal of concomitant treatment with antiepileptic drugs in the same patient, the daily PHT dose was calculated using the value of each ratio or its reciprocal. Our results could be helpful in determining PHT dosing.
本研究寻找与每日苯妥英(PHT)剂量(D)相关的合适生理参数,以提供稳态血清浓度(Ct),并定量分析联合使用的抗癫痫药物对Ct的影响,从而调整PHT剂量。数据来自总共368例接受多次口服PHT治疗的癫痫患者。同时给予苯巴比妥、卡马西平、丙戊酸、唑尼沙胺、氯硝西泮和乙琥胺。对于单独使用PHT的情况,研究了4种参数,即总体重、总体液量、体表面积和细胞外液量(VECW)。然后,假定了一个包含VECW的米氏动力学模型,该模型被认为可以定量检测联合使用药物的效果。采用VECW作为转换因子,浓度与剂量(L:D)比[Ct/(D/VECW)]在与Ct相关的方面与患者年龄和性别无关,并表示为Ct/(D/VECW)=0.0245×Ct+0.076。分析表明,为维持相同的PHT Ct浓度,苯巴比妥、卡马西平、丙戊酸和唑尼沙胺的比值分别估计为0.90、0.91、0.89和0.84。无论因素类型如何,未检测到联合使用药物数量(≥2)增加时的影响。PHT清除率以年龄依赖性方式变化,通常与基于体重的剂量相关性较差。VECW与清除率等生理参数的年龄依赖性变化更密切相关。VECW被认为可以消除年龄对清除率的影响,估计的比值可用于所有年龄组。在同一患者中添加或去除抗癫痫药物的联合治疗时,使用每个比值或其倒数的值计算每日PHT剂量。我们的结果可能有助于确定PHT给药剂量。